Text Size

Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)

This study has been completed.
Sponsor:
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Dr Lemuel A Moye III, The University of Texas Health Science Center, Houston
ClinicalTrials.gov Identifier:
NCT00684060
First received: May 22, 2008
Last updated: January 18, 2013
Last verified: January 2013
History of Changes
Results First Received: April 9, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Left Ventricular Dysfunction
Interventions: Biological: Adult stem cells
Biological: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Enrollment took place at five Network centers and their associated satellite facilities between July 8, 2008 and February 28, 2011. The main centers are located in Ohio, Texas, Florida, Minnesota, and Tennessee. Study brochures, patient informational DVDs, and clinical trials.gov were among the tools used for recruitment.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Stem Cell Arm Participants will receive active stem cell infusion 2 to 3 weeks after a percutaneous coronary intervention (PCI).
Placebo Arm Participants will receive placebo infusion (5% human serum albumin [HSA]) 2 to 3 weeks after a PCI.

Participant Flow:   Overall Study
    Stem Cell Arm     Placebo Arm  
STARTED     58     29  
COMPLETED     55     26  
NOT COMPLETED     3     3  
Lost to Follow-up                 1                 0  
New stenosis identified                 1                 0  
Unable to collect MRI                 1                 2  
Death                 0                 1  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Stem Cell Arm Participants will receive active stem cell infusion 2 to 3 weeks after a percutaneous coronary intervention (PCI).
Placebo Arm Participants will receive placebo infusion (5% human serum albumin [HSA]) 2 to 3 weeks after a PCI.
Total Total of all reporting groups

Baseline Measures
    Stem Cell Arm     Placebo Arm     Total  
Number of Participants  
[units: participants]
 		  58     29     87  
Age  
[units: years]
Mean ± Standard Deviation 		  57.6  ± 11     54.6  ± 11     57  ± 11  
Gender  
[units: participants]
 		     
Female     12     3     15  
Male     46     26     72  
Region of Enrollment  
[units: participants]
 		     
United States     58     29     87  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Global Left Ventricular Function   [ Time Frame: Measured at Baseline and Month 6 ]
  Show Outcome Measure 1

2.  Primary:   Regional Left Ventricular Function (Infarct Zone Wall Motion)   [ Time Frame: Measured at Baseline and Month 6 ]
  Hide Outcome Measure 2

Measure Type Primary
Measure Title Regional Left Ventricular Function (Infarct Zone Wall Motion)
Measure Description One of two calculated values of regional left ventricular function as assessed via cardiac MRI. The infarct zone is defined as the cMRI segments with the largest 2 signal intensity enhancement measures with gadolinium (using a 17-segment model).Values reported represent the change in wall motion over time in the infarct zone from baseline to six months.
Time Frame Measured at Baseline and Month 6  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.

Only participants with both baseline and 6 month MRI images available are included. One patient was excluded from the analysis due to incomplete signal intensity enhancement data.

Values reported represent the change in wall motion over time in the infarct zone from baseline to six months.

Reporting Groups
  Description
Stem Cell Arm Participants will receive active stem cell infusion 2 to 3 weeks after a percutaneous coronary intervention (PCI).
Placebo Arm Participants will receive placebo infusion (5% human serum albumin [HSA]) 2 to 3 weeks after a PCI.

Measured Values
    Stem Cell Arm     Placebo Arm  
Number of Participants Analyzed  
[units: participants]
 		  55     25  
Regional Left Ventricular Function (Infarct Zone Wall Motion)  
[units: mm]
Mean ± Standard Deviation 		  0.3  ± 4.3     1.0  ± 4.5  


Statistical Analysis 1 for Regional Left Ventricular Function (Infarct Zone Wall Motion)
Groups [1] All groups
Method [2] t-test, 2 sided
P Value [3] <0.05
Mean Difference (Net) [4] -0.7
Standard Error of the mean ± 4.4
95% Confidence Interval ( -2.8 to 1.3 )
[1] Additional details about the analysis, such as null hypothesis and power calculation:
  Comparison of change in infarct zone wall motion in the active group minus change in global LVEF in the control group. 80 percent power based on BOOST results
[2] Other relevant information, such as adjustments or degrees of freedom:
  No text entered.
[3] Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
  Unadjusted
[4] Other relevant estimation information:
  No text entered.



3.  Primary:   Regional Left Ventricular Function (Border Zone Wall Motion)   [ Time Frame: Measured at Baseline and Month 6 ]
  Show Outcome Measure 3

4.  Secondary:   Combined Endpoint   [ Time Frame: Measured at Baseline and Month 6 ]
  Show Outcome Measure 4

5.  Secondary:   Left Ventricular Mass   [ Time Frame: Measured at Baseline and Month 6 ]
  Show Outcome Measure 5

6.  Secondary:   End Diastolic Volume Index   [ Time Frame: Measured at Baseline and Month 6 ]
  Show Outcome Measure 6

7.  Secondary:   End Systolic Volume Index   [ Time Frame: Measured at Baseline and Month 6 ]
  Hide Outcome Measure 7

Measure Type Secondary
Measure Title End Systolic Volume Index
Measure Description Left ventricular end systolic volume index. Values reported represent the change in LV end systolic volume index from baseline to six months.
Time Frame Measured at Baseline and Month 6  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.

Only participants with both baseline and 6 month MRI images available are included.

Values reported represent the change in LV end systolic volume index from baseline to six months.

Reporting Groups
  Description
Stem Cell Arm Participants will receive active stem cell infusion 2 to 3 weeks after a percutaneous coronary intervention (PCI).
Placebo Arm Participants will receive placebo infusion (5% human serum albumin [HSA]) 2 to 3 weeks after a PCI.

Measured Values
    Stem Cell Arm     Placebo Arm  
Number of Participants Analyzed  
[units: participants]
 		  55     26  
End Systolic Volume Index  
[units: mL/m2]
Mean ± Standard Deviation 		  0.2  ± 14.0     -2.3  ± 14.7  


Statistical Analysis 1 for End Systolic Volume Index
Groups [1] All groups
Method [2] t-test, 2 sided
P Value [3] <0.05
Mean Difference (Net) [4] 2.5
Standard Error of the mean ± 14.2
95% Confidence Interval ( -4.1 to 9.2 )
[1] Additional details about the analysis, such as null hypothesis and power calculation:
  Comparison of change in the active group minus change in the control group.
[2] Other relevant information, such as adjustments or degrees of freedom:
  No text entered.
[3] Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
  No text entered.
[4] Other relevant estimation information:
  No text entered.



8.  Secondary:   Infarct Volume   [ Time Frame: Measured at Baseline and Month 6 ]
  Show Outcome Measure 8


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Lack of in-vivo testing of cell product. While there are several different approaches to measure myocardial strain (myocardial tagging, DENSE, etc.), these were not employed in this study due to the need for specialized expertise at each site.  


Results Point of Contact:  
Name/Title: Lemuel Moye, MD, PhD
Organization: UT-Houston School of Public Health
phone: 713-500-9518
e-mail: Lemmoye@msn.com


Publications of Results:

Other Publications:


Responsible Party: Dr Lemuel A Moye III, The University of Texas Health Science Center, Houston
ClinicalTrials.gov Identifier: NCT00684060     History of Changes
Other Study ID Numbers: 578, 1U01HL087318, 1 U01-HL-087318-01 (Project 2)
Study First Received: May 22, 2008
Results First Received: April 9, 2012
Last Updated: January 18, 2013
Health Authority: United States: Food and Drug Administration